(firstQuint)A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer.

 All Subjects will receive AGS-8M4 treatment.

 Subjects will be enrolled sequentially into 1 of the 4 planned dose cohorts according to a standard dose escalation study design.

 A disease assessment will be performed at study week 9 (+/- 3 days).

 The assessment will be based on clinical signs and symptoms, changes in radiographic images, and changes in CA-125 levels.

 Subjects without evidence of disease progression may continue to receive AGS-8M4 during the extended treatment period at the dose and schedule of their assigned cohort until disease progression intolerability of AGS-8M4 or consent withdrawal.

 For subjects that continue dosing, disease assessments will be performed every 8 weeks during the extended treatment period.

 A safety follow-up visit will occur 4 weeks after the last infusion of AGS-8M4.

.

 A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer@highlight

This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer.

 AGS-8M4 will be administered as an IV infusion until the disease worsens.

